Treatment Adherence in MS: Does Objective MS Knowledge and MS Risk Knowledge Matter in Relation to Perceived Disease-Modifying Therapy Benefits?

IF 4.8 3区医学 Q1 CLINICAL NEUROLOGY

Neurology and Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-13 DOI:10.1007/s40120-025-00806-x

Edward Smith, Dawn Langdon

{"title":"Treatment Adherence in MS: Does Objective MS Knowledge and MS Risk Knowledge Matter in Relation to Perceived Disease-Modifying Therapy Benefits?","authors":"Edward Smith, Dawn Langdon","doi":"10.1007/s40120-025-00806-x","DOIUrl":null,"url":null,"abstract":"Introduction: The effectiveness of disease-modifying therapies (DMTs) in managing MS has been established, although adherence is commonly difficult to achieve, which can undermine health outcomes. People with MS (pwMS) who perceive greater benefits from DMTs are more likely to report being adherent. This pilot study investigated the extent to which knowledge of MS and its risks contributes to this relationship. Knowledge is modifiable and may enhance adherence.Methods: Sixty-three pwMS were recruited through MS charity webpages and social media to take part in an anonymous online survey including validated measures of perceived adherence benefits, perceived MS susceptibility, MS knowledge, MS risk knowledge and self-reported treatment adherence.Results: In a hierarchical regression, greater perceived treatment adherence benefit was significantly associated with higher levels of self-reported adherence (B = 0.20, β = 0.27, t(59) = 2.16, p = 0.04). Interestingly, adding objective measures of MS knowledge F(2,61) = 0.96, p = 0.33) and subsequently MS risk knowledge (F(3,59) = 2.29, p = 0.14) did not significantly change variance in self-reported adherence.Conclusion: An individual's subjective evaluation of DMT benefits seems to be a key driver in treatment adherence, possibly reflecting the individual and cultural context. Interventions which centre on patient perceived benefit may be more effective in supporting adherence.","PeriodicalId":19216,"journal":{"name":"Neurology and Therapy","volume":" ","pages":"2107-2123"},"PeriodicalIF":4.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450202/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40120-025-00806-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The effectiveness of disease-modifying therapies (DMTs) in managing MS has been established, although adherence is commonly difficult to achieve, which can undermine health outcomes. People with MS (pwMS) who perceive greater benefits from DMTs are more likely to report being adherent. This pilot study investigated the extent to which knowledge of MS and its risks contributes to this relationship. Knowledge is modifiable and may enhance adherence.

Methods: Sixty-three pwMS were recruited through MS charity webpages and social media to take part in an anonymous online survey including validated measures of perceived adherence benefits, perceived MS susceptibility, MS knowledge, MS risk knowledge and self-reported treatment adherence.

Results: In a hierarchical regression, greater perceived treatment adherence benefit was significantly associated with higher levels of self-reported adherence (B = 0.20, β = 0.27, t(59) = 2.16, p = 0.04). Interestingly, adding objective measures of MS knowledge F(2,61) = 0.96, p = 0.33) and subsequently MS risk knowledge (F(3,59) = 2.29, p = 0.14) did not significantly change variance in self-reported adherence.

Conclusion: An individual's subjective evaluation of DMT benefits seems to be a key driver in treatment adherence, possibly reflecting the individual and cultural context. Interventions which centre on patient perceived benefit may be more effective in supporting adherence.

Abstract Image

查看原文本刊更多论文

多发性硬化症的治疗依从性：客观的多发性硬化症知识和多发性硬化症风险知识与感知到的疾病改善治疗益处有关吗？

疾病修饰疗法（dmt）在治疗多发性硬化症方面的有效性已经确立，尽管坚持治疗通常很难实现，这可能会损害健康结果。认为从dmt中获益更大的多发性硬化症（pwMS）患者更有可能报告自己的依从性。这项初步研究调查了对多发性硬化症及其风险的了解对这种关系的影响程度。知识是可修改的，可以增强坚持。方法：通过多发性硬化症慈善网站和社交媒体招募63名多发性硬化症患者参加匿名在线调查，包括感知依从性获益、感知多发性硬化症易感性、多发性硬化症知识、多发性硬化症风险知识和自我报告的治疗依从性。结果：在分层回归中，更高的治疗依从性获益与更高的自我报告依从性水平显著相关（B = 0.20, β = 0.27, t(59) = 2.16, p = 0.04）。有趣的是，增加MS知识（F(2,61) = 0.96, p = 0.33）和MS风险知识（F(3,59) = 2.29, p = 0.14）的客观测量并没有显著改变自我报告依从性的方差。结论：个体对DMT益处的主观评价似乎是治疗依从性的关键驱动因素，可能反映了个体和文化背景。以患者感知利益为中心的干预措施在支持依从性方面可能更有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurology and Therapy CLINICAL NEUROLOGY-

CiteScore

5.40

自引率

8.10%

发文量

103

审稿时长

6 weeks

期刊介绍： Aims and Scope Neurology and Therapy aims to provide reliable and inclusive, rapid publication for all therapy related research for neurological indications, supporting the timely dissemination of research with a global reach, to help advance scientific discovery and support clinical practice. Neurology and Therapy is an international, open access, peer reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world and health outcomes research around the discovery, development, and use of neurological and psychiatric therapies, (also covering surgery and devices). Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also welcomed. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, case reports, trial designs, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Neurology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted, it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model, this allows for the rapid and efficient communication of the latest research and reviews to support scientific discovery and clinical practice. Open Access All articles published by Neurology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital Features and Plain Language Summaries Neurology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case-by-case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviews conflict, an Editorial Board Member will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed. Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised, it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor, and authors are welcome to make rebuttals against individual reviewer comments, if appropriate. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Neurology and Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.